Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Evandro de Azambuja

45PUBLICATIONS
209CO-AUTHORS
Molecular targetsPredictive and prognostic markersFood properties (incl. characteristics and health benefits)Cancer therapy (excl. chemotherapy and radiation therapy)Environmental epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (45)

Sort by Publication Date:
|Jul 10, 2026
EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.

|Jan 21, 2026
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.

Sara M Tolaney, Evandro de Azambuja, Kevin Kalinsky

|Jun 13, 2025
Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study.

Karen Van Baelen, Ha-Linh Nguyen, François Richard

|Apr 28, 2025
Impact of Dietary Supplements on Clinical Outcomes and Quality of Life in Patients with Breast Cancer: A Systematic Review.

Luca Scafuri, Carlo Buonerba, Oriana Strianese

|Oct 01, 2024
Response to letter "re: Surgery of the primary tumor in patients with de novo metastatic breast cancer: A nationwide population-based retrospective cohort study in Belgium and the National Cancer Database (NCDB)".

Diogo Martins-Branco, Mariana Brandão, Evandro de Azambuja

|Sep 11, 2024
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.

Sibylle Loibl, Jacek Jassem, Amir Sonnenblick

Pageof 8

Frequent Collaborators

9 joint publications

Martine Piccart-Gebhart

9 joint publications

Matteo Lambertini

6 joint publications

Diogo Martins-Branco

6 joint publications

Mariana Brandão

5 joint publications

Richard Gelber

5 joint publications

Nadia Harbeck

5 joint publications

Elisa Agostinetto

5 joint publications

Paolo Nuciforo

4 joint publications

Daniel Eiger

4 joint publications

Kevin Punie

Frequent Collaborators

9 joint publications

Martine Piccart-Gebhart

9 joint publications

Matteo Lambertini

6 joint publications

Diogo Martins-Branco

6 joint publications

Mariana Brandão